



STATE MEDICAID P&T COMMITTEE MEETING  
THURSDAY, June 18, 2009  
7:00 a.m. to 8:30 a.m.  
Cannon Health Building  
Room 125



## MINUTES

**Committee Members Present:**

**Kort DeLost, R.Ph.**

**Duane Parke, R.Ph.**

**Karen Gunning, PharmD.**

**Ellie Brownstein, M.D.**

**Michael Flynn, M.D.**

**Raymond Ward, M.D.**

**Koby Taylor, PharmD.**

**Board Members Excused:**

**Jerome Wohleb, PharmD.**

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Jennifer K. Zeleny, CPhT., MPH

Lisa Hulbert, R.Ph.

**University of Utah Drug Information Center Staff Present:**

David Peterson, PharmD.

**Other Individuals Present:**

Sedrick Spencer, Roche

John Stockton, Genentech

Lori Blackne, Pfizer

Megan Evans, NA

Courtney Mckinney, Student

Mark Alden, Roche

Lori Howarth, Bayer

Alan Bailey, Pfizer

Sonya Kousoum, Student

Ryan Nielson, Student

Meeting conducted by: Koby Taylor, PharmD., Co-Chairperson.

- 
1. Minutes for June 2009 were reviewed, corrected, and approved. Dr. Ward moved to approve the minutes. Kort DeLost seconded the motion. The motion passed with unanimous votes from Dr. Ward, Kort DeLost, Koby Taylor, Karen Gunning, and Duane Parke.
  2. DUR Board Update: Lisa Hulbert addressed the Committee. The next meeting will be August 13. The DUR Board will be looking at Cancidas criteria, finishing the Fibromyalgia class of medications. The DUR Board will also consider insulin quantity limits, and reviewing Avastin and Lamisil PA criteria. In the last couple of months, the DUR Board has updated criteria for topical acne, eliminated coverage for some barbiturates, and limited coverage for smoking cessation. Criteria for various drug products have also been updated.

3. P&T Committee Update: Duane Parke addressed the Committee. Medicaid has gotten authorization to have Nasonex and generic Fluticasone as the preferred drugs in the nasal corticosteroid class. Medicaid is still waiting for management approval on osteoporosis agents and anti-parkinson's agents.

P&T Committee members were provided with a report on program savings on the Preferred Drug List program.

4. Hepatitis C Agents: Dr. David Peterson from the University of Utah Drug Regimen Review Center addressed the Committee. Findings from the Oregon Health Sciences center were reviewed. Updated information from the Drug Information Service was also presented.

Dr. Flynn asked if Dr. Peterson had a copy of the IDEAL study referenced on page 17 on the OHSU document. Dr. Peterson was not able to locate the study and was not sure if it was ever completed and published.

Duane mentioned that he had found another head-to-head trial referenced in the OHSU document.

Mark Alder, PharmD., from Roche addressed the Committee regarding the benefits of Pegasys for Hepatitis C, and some unique indications of this drug.

The Committee asked if some of the head-to-head trials with PegIntron that showed statistically significant differences were published in peer-reviewed journals. These studies have been presented, but have not been published in peer-reviewed journals.

Duane Parke provided Medicaid utilization data to the P&T Committee.

Dr. Ward noted that the published trials do not show any differences, and many providers consider the two interferons to be very similar. If anything, the slight advantage that Pegasys may appear to have in some unpublished trials may be due to the fact that the standard dose is higher based on the weight of lighter individuals.

Karen Gunning felt that it may be appropriate to re-review the class when head-to-head trials are published. The DUR Board should also check to see whether or not ribavirin is being prescribed concomitantly. She asked the pediatricians on the Committee if a pediatric indication needs to be considered.

The pediatricians on the Committee stated that children may be screen for Hepatitis C, but are not routinely treated. Dr. Ward added that children seem to not suffer any ill effects from the disease for the first 20 or so years of their life anyway.

1. Dr. Ward moved that the Committee finds that they cannot find any significant differences between the two agents in the class, and the Department should make a decision based on cost. The class should be re-

reviewed as more of the head-to-head trials are published. Dr. Flynn seconded the motion. The motion passed with unanimous votes from Dr. Ward, Kort DeLost, Koby Taylor, Karen Gunning, Dr. Flynn, Dr. Brownstein, and Duane Parke.

Next Meeting Set for Thursday, August 20, 2009  
Meeting Adjourned.

Minutes prepared by Jennifer Zeleny